HP
SMMT icon

Havemeyer Place’s Summit Therapeutics SMMT Stock Holding History

Havemeyer Place’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.2K Sell
6,120
-55,869
-90% -$991K 0.01% 480
2026
Q1 		$1.18M Buy
61,989
+55,735
+891% +$901K 0.14% 282
2025
Q4 		$109K Buy
+6,254
New +$118K 0.02% 464

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Havemeyer Place's SMMT Position: Q2 2026 in Review

Havemeyer Place reduced its Summit Therapeutics (SMMT) stake by 90% in Q2 2026, selling an estimated $991K and leaving 6,120 shares worth $89.2K. The position accounts for 0.01% of the portfolio, ranked #480.

Havemeyer Place first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.18M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Havemeyer Place held 6,120 shares of Summit Therapeutics worth $89.2K as of Q2 2026.
  • Havemeyer Place sold 55,869 Summit Therapeutics shares in Q2 2026, an estimated $991K.
  • Summit Therapeutics made up 0.01% of Havemeyer Place's portfolio in Q2 2026, its #480 holding.
  • Havemeyer Place first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Havemeyer Place's Summit Therapeutics position peaked at $1.18M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Havemeyer Place's 13F filing for Q2 2026, filed 13 Aug 2026.